Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) has issued an announcement.
Hangzhou Tigermed Consulting Co., Ltd. has announced that its Board of Directors will meet on March 27, 2025, to review and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the recommendation for a final dividend payment, which could impact shareholder returns and reflect the company’s financial health.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating with limited liability. The company is involved in the consulting industry, providing services that likely include clinical research and development support, which are crucial for pharmaceutical and biotechnology sectors.
YTD Price Performance: 19.13%
Average Trading Volume: 328
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €5.49B
Learn more about 3347 stock on TipRanks’ Stock Analysis page.